Multiple large-scale phase III randomized controlled trials, including KEYNOTE-859, CheckMate-649, ATTRACTION-4, ORIENT-16, and RATIONALE-305, have demonstrated that combining immunotherapy with chemotherapy significantly improves the ORR and prolongs PFS and OS in patients with previously untreated HER2-negative advanced gastric cancer (14–18). This evidence concerns the gene ERBB2 and gastric cancer.